FENC Stock Analysis: Buy, Sell, or Hold?
FENC - Fennec Pharmaceuticals Inc. Common Stock
$9.59
0.02 (0.21%)
▲
5d:
-6.07%
30d:
-10.37%
90d:
+46.64%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When FENC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: FENC is fairly valued with market pricing in 1.0% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: FENC is fairly valued with market pricing in 1.0% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.20
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.30
15.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FENC is currently trading at $9.59, which is considered oversold relative to its 30-day fair value range of $9.94 to $10.78. The stock's valuation (Forward PE: 10.8) is in line with its historical norms (10.5). At these levels, the market is pricing in 1.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FENC is in a strong uptrend. The price is currently testing key support at $9.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.67 (+63.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FENC is in a strong uptrend. The price is currently testing key support at $9.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.67 (+63.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.94 -
$10.78
Company Quality Score
58/100
(HOLD)
Options IV Signal
20th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 20th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 63.4% below Wall St target ($15.67)
- NEUTRAL: Market pricing in 1.0% annual earnings growth - fairly valued
- CAUTION: Recommendation downgraded due to -6.1% 5-day decline
Trading Range Analysis
30-Day Trading Range
$9.94 -
$10.78
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.08
(11.3%)
Support & Resistance Levels
Support Level
$9.40
Resistance Level
$10.75
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.78
Wall Street Target
$15.67
(+63.4%)
Revenue Growth (YoY)
72.6%
Profit Margin
-16.4%
Valuation Premium vs History
+1.0% premium
PE vs Historical
10.8 vs 10.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.0%
(market-implied from PE analysis)
1-Year Target
$9.69
(+1%)
2-Year Target
$9.78
(+2%)
3-Year Target
$9.88
(+3%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
PE COMPRESSION
$9.63
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 200.7%)
$62.27
(+549%)
Base:
(SPY PE: 10.8, Growth: 200.7%)
$32.37
(+238%)
Bear:
(PE: 9.2, Growth: 200.7%)
$27.51
(+187%)
Share & Embed Analysis
Last updated: August 03, 2026 8:22 PM ET
Data refreshes hourly during market hours. Next update: 9:22 PM
Data refreshes hourly during market hours. Next update: 9:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FENC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Rosty Raykov
SELL
10946 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
